The findings address a twofold disadvantage documented in the study's framing: minority and underserved youth with diabetes are less likely to undergo diabetic retinopathy screening, yet more likely to have the condition. The ACCESS2 study hypothesized that autonomous AI-based diabetic eye exams could mitigate these screening disparities, and tested that hypothesis by embedding the exam directly into routine diabetes care visits rather than relying on a separate referral pathway. The study was registered as NCT05463289.

Participants were young people with type 1 diabetes, who made up 72% of the cohort, and type 2 diabetes, who accounted for 28%. All enrolled participants underwent the autonomous AI diabetic eye exam along with optical coherence tomography imaging during their diabetes care visits. Diagnostic performance was assessed against a prognostic standard using standard grading as the comparison.

For detecting more than mild diabetic retinopathy, the AI achieved a sensitivity of 100%, with a 95% confidence interval ranging from 67.6% to 100%, meaning no cases in this cohort were missed. Specificity was 76%, with a 95% confidence interval of 71.4% to 79.9%, indicating that roughly a quarter of eyes without the condition were flagged as positive. The equivalence in screening completion was demonstrated against a prespecified criterion rather than assumed.

The primary outcome compared completion rates between White and non-White youth after the AI intervention, and the near-identical rates of 99.5% and 98% satisfied it. This contrasts sharply with the baseline disparity in prior screening history that the researchers documented before any exposure to the AI exam. Even so, the authors describe the findings as suggesting the potential to reduce disparities in diabetic retinopathy screening, rather than proving a sustained reduction in retinopathy outcomes over time, and the results come from the specific study population and setting reported.

Subject of Research: Autonomous AI diabetic retinopathy screening to reduce disparities in youth with diabetes

Article Title: ACCESS2 study: the potential for autonomous AI to mitigate disparities in diabetic retinopathy screening in youth

Article References: Wolf, R. M., Channa, R., Liu, T. Y. A., Brown, E. A., Bromberger, L., Parimi, N., Zehra, A., Patel, D., Pan, B., Kim, Y. C., Shehadeh, A., Lehmann, H. P., & Abramoff, M. D. (2026). ACCESS2 study: the potential for autonomous AI to mitigate disparities in diabetic retinopathy screening in youth. Nature Communications. https://doi.org/10.1038/s41467-026-78842-w

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78842-w

Keywords: autonomous AI, diabetic retinopathy, screening disparities, youth, type 1 diabetes, type 2 diabetes, point-of-care diagnostics, optical coherence tomography, health equity, ACCESS2 study, Nature Communications, prospective study

Skeletal complications can arise from both malignant disease and its treatment. The study describes cancer treatment–induced bone loss as a multifactorial process involving systemic inflammation, reduced physical activity, nutritional deficiencies and exposure to treatments such as chemotherapy, radiotherapy, endocrine therapy, glucocorticoids and hematopoietic stem-cell transplantation. These factors can act together to increase bone turnover, reduce bone mineral density and elevate fracture risk. Bone loss associated with cancer therapies is particularly well established in hormone-sensitive malignancies, including breast and prostate cancer, where aromatase inhibitors and androgen-deprivation therapy are linked to accelerated bone loss. However, population-based evidence described by the researchers indicates that fracture risk is elevated across a broader range of cancers and can persist for years after diagnosis.

Despite that wider risk, guidelines from major oncology and endocrine organizations recommend DXA for people at increased skeletal risk, especially those exposed to bone-toxic therapies. The researchers also note that osteoporosis risk-assessment tools can underestimate fracture risk in cancer survivors and that malignancy is not consistently incorporated into fracture-prediction models. Their retrospective cohort used the MDClone platform to extract fully anonymized, statistically accurate data from electronic medical records at Assuta, a private healthcare network operated by Maccabi Healthcare Services. Eligible participants were adults with a first documented cancer diagnosis and complete demographic information. Mean age was 60.2 years, 77.0% were women, and mean body-mass index was 26.7 kg/m². Chemotherapy exposure was recorded in 21.4% of patients and radiotherapy in 7.0%.

Assessment patterns differed sharply according to sex and cancer type. Women were more likely than men to undergo DXA, with utilization rates of 41.7% and 15.0%, respectively. Breast cancer had the highest rate of testing at 42.2%, followed by prostate cancer at 30.0%, while rates were generally below 15% for lung, gastrointestinal, ovarian and pancreatic cancers. In a multivariable logistic regression, female sex was associated with greater odds of DXA assessment than male sex, with an adjusted odds ratio of 2.13 and a 95% confidence interval of 1.79–2.50. Each additional year of age was associated with slightly higher odds, while breast and prostate cancer were associated with adjusted odds ratios of 5.82 and 5.29, respectively, compared with other cancer types. These associations describe testing patterns rather than proving why individual scans were ordered or omitted.

Timing was similarly uneven. Only 14.1% of the full cohort underwent DXA during the first 12 months after diagnosis. Among all patients who eventually received a scan, the median time to assessment was 14.8 months. Median timing was 12.9 months for breast cancer, with an interquartile range of 5.8–28.0 months, and 12.7 months for prostate cancer, with an interquartile range of 4.4–28.8 months. Patients with other malignancies waited longer: their median time to DXA was 17.9 months, with an interquartile range of 8.3–35.1 months. Men and women who were assessed had broadly comparable timing, indicating that the largest sex difference concerned whether a scan occurred at all rather than the interval among those who received one.

Bone density was frequently abnormal when the scans finally occurred. The analysis of bone-density outcomes included 5,570 tested patients with complete, evaluable measurements. Using the lowest T-score from the lumbar spine, femoral neck or total hip, 40.2% had normal bone mineral density, 45.2% met the criteria for osteopenia and 14.5% met the criteria for osteoporosis. The mean lowest T-score was −1.72 among patients classified as osteopenic and −2.95 among those classified as osteoporotic. Site-specific results showed the least favorable average T-score at the femoral neck, at −1.14, compared with −0.83 at the total hip and −0.54 at the lumbar spine. Osteopenia was most frequent at the femoral neck, affecting 50.3% of patients with available site-level measurements, while osteoporosis was most common at the lumbar spine at 10.2%.

These measurements show a large burden of low bone mass among people who reached DXA, but they do not establish when the bone loss began or what caused it. Abnormal density may have predated the cancer diagnosis, and the retrospective data could not uniformly capture histology, disease stage, treatment dose or duration, lifestyle factors and other influences on skeletal health. The investigators could not systematically identify hematopoietic stem-cell transplantation, and DXA examinations performed outside Assuta may not have been captured. Fracture outcomes were not analyzed, so the study could not determine whether delayed testing was associated with more fractures. DXA completion was also used as a surrogate for bone-health evaluation, even though some patients without a recorded scan may have met osteoporosis criteria through other clinical information. These restrictions prevent the findings from establishing a causal effect of the testing gap on skeletal outcomes.

The analysis nevertheless points to missed opportunities for earlier skeletal risk identification. The researchers proposed several potential ways to make assessment more systematic, but did not test the effectiveness of these approaches. Electronic oncology records could issue automated DXA-referral prompts when a cancer is diagnosed or when a patient starts treatment likely to affect bone. Bone-health evaluation could be integrated into standardized survivorship-care plans and multidisciplinary tumor reviews, including for cancers less consistently covered by endocrine-therapy guidance. Dedicated referral pathways were also proposed for patients receiving chemotherapy, radiotherapy or glucocorticoids. Because the study documented substantially lower use among men, the authors suggested targeted education and closer collaboration among oncology, endocrinology and specialist bone-health services, while acknowledging the need to determine whether such measures improve assessment and outcomes.

Uncertainty remains particularly relevant for newer systemic therapies, including immune checkpoint inhibitors and targeted agents. The study notes that their long-term effects on bone mineral density and fracture outcomes remain incompletely characterized. A cited meta-analysis of randomized trials involving more than 19,000 patients associated immune checkpoint inhibitor use with a nonsignificant 18% increase in clinical fracture incidence relative to controls, with an odds ratio of 1.18 and a 95% confidence interval of 0.82–1.70. Because fractures were infrequently reported and the confidence interval included no effect, the estimate was imprecise and does not establish a fracture-causing effect. The present study also had broader generalizability limitations: it included one healthcare network in a specific national insurance system, did not consistently capture ethnicity, and may have enrolled a less complex case mix than the wider Israeli cancer population. Within those boundaries, the results show that DXA after cancer diagnosis was selectively delivered and frequently late, with abnormal bone density already common when assessment occurred.

Subject of Research: Real-world DXA utilization, timing and bone-mineral-density outcomes after cancer diagnosis

Article Title: Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care

Article References: Rouach, V., Versano, Z., Sasson, M., Greenman, Y., & Makori, A. (2026). Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care. Supportive Care in Cancer, 34(11), Article 1124. https://doi.org/10.1007/s00520-026-11340-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11340-3

Keywords: cancer survivorship, bone density, DXA, osteoporosis, osteopenia, fracture risk, screening disparities, real-world cohort, cancer treatment, Delayed, selective, bone

That gap is the target of a new study published in BMC Health Services Research. Led by Anand K. Narayan of the University of Wisconsin School of Medicine and Public Health, the research team describes the design of an implementation blueprint: a structured, fill-in-the-blanks template that guides cancer centers and imaging practices through the development, deployment, and evaluation of interventions to raise mammography screening rates among underserved patient populations. The work emerged from a 2023 initiative in which the American College of Radiology and the Radiology Health Equity Coalition sponsored participation in the National Academy of Medicine Scholars in Diagnostic Excellence program, an effort to develop strategies for reducing care gaps that limit access to timely, high-quality screening and diagnostic breast imaging.

The central insight of the paper is that the tools of implementation science, a discipline devoted to understanding how evidence-based practices get adopted in real-world settings, can be fused with the familiar machinery of quality improvement. Rather than asking clinicians to master an entirely new methodology, the authors adapted a validated A3 quality improvement template, a one-page problem-solving format with demonstrated reliability, measurement, content, and construct validity, and rebuilt it around published implementation science determinants, process, and evaluation frameworks. They drew on training courses and resources from the National Cancer Institute’s health-equity focused implementation toolkit to ensure that equity considerations were embedded at every step rather than bolted on afterward.

The resulting blueprint contains eight sections: Problem, Targets, Current Situation, Determinants, Evidence-Based Practice Intervention, Recommendations, Action Plan, and Sustain and Follow-Up. Each section translates a conceptual framework into a concrete task. The problem statement is written with health equity in mind, naming the specific patient population experiencing increased deaths from breast cancer. The target is expressed as a SMART goal, meaning it is Specific, Measurable, Achievable, Relevant, and Time-Bound, so that progress can be tracked rather than merely aspired to.

One of the most technically interesting components is the modification of the classic fishbone diagram, a cause-and-effect visualization long used in industrial and clinical quality improvement, using the Consolidated Framework for Implementation Research, known as CFIR. CFIR organizes the determinants of implementation success across five domains: the intervention itself, the outer setting, the inner setting, the characteristics of individuals, and the implementation process. By pairing CFIR domains with explicit health equity questions, the blueprint prompts teams to identify barriers and facilitators to cancer screening that they might otherwise overlook, such as how clinic hours, language access, or historical mistrust shape whether women in the target population actually book and complete a mammogram.

Identifying barriers is only half the battle; the blueprint then requires teams to match those barriers to discrete implementation strategies. For this, the authors turned to the CFIR-ERIC mapping tool, which links determinants identified through CFIR to the Expert Recommendations for Implementing Change, a catalog of 73 discrete implementation strategies compiled from a systematic review of the literature. A key driver diagram in the blueprint maps each identified barrier to a corresponding strategy, creating a traceable chain from problem to solution. This mapping discipline matters because implementation strategies deployed without a clear rationale for why they should work in a given setting are a well-documented source of wasted effort in quality improvement.

The blueprint also builds evaluation and sustainability into the action plan rather than treating them as afterthoughts. Action plans include tracking health equity focused implementation outcomes, so teams can see whether the intervention is actually narrowing the gap for the named population. Determinants of program sustainability are assessed with the Program Sustainability Assessment Tool, or PSAT, which evaluates factors such as funding stability, partnerships, organizational capacity, and program evaluation. The framework repertoire the authors draw on is broad, encompassing the Organizational Readiness for Implementing Change measure, the Practical, Robust Implementation and Sustainability Model, and Plan-Do-Study-Act cycles, along with the Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies for documenting how interventions are tailored in practice.

Why does this matter now? The authors frame their contribution as a pivot point for the field. Over several decades, health services research has generated key insights about the multilevel drivers of cancer health disparities, but the next phase, they contend, should leverage those insights to design, implement, and rigorously evaluate interventions rather than continuing to catalog determinants. Implementation science process, determinants, and evaluation frameworks offer methods to accelerate dissemination and advance disparities research, and packaging them inside a validated quality improvement template lowers the barrier to entry for cancer centers that lack dedicated implementation science expertise. The Radiology Health Equity Coalition, convened by the American College of Radiology, brings together patient-focused radiology societies to collect, assess, and disseminate resources and best practices, providing a ready dissemination channel for the blueprint.

The technical scaffolding also reflects a shift in how the radiology community measures quality itself. The abbreviations woven through the paper, from BI-RADS, the Breast Imaging Reporting and Data System, to positive predictive value measures used to assess the cancer yield of biopsies, signal that the blueprint is designed for teams who already track imaging performance metrics and now need to track equity metrics with the same rigor. Electronic clinical quality improvement resources from the Agency for Healthcare Research and Quality and the Centers for Medicare and Medicaid Services are positioned as data infrastructure for measuring screening percentages and follow-up outcomes across patient populations.

The study was supported by the Susan G. Komen Foundation Career Catalyst Award and the University of Wisconsin Carbone Cancer Center Support Grant, and the authors declare no competing interests. Published open access on 15 October 2026, the paper offers its blueprint as an actionable template rather than a finished intervention, and its real test will come as cancer centers pick it up, adapt it with the Plan-Do-Study-Act cycles it prescribes, and report whether mammography screening rates rise in the populations where deaths from breast cancer remain highest. If the blueprint succeeds in standardizing how equity-focused implementation is planned and evaluated, it could mark the moment when reducing cancer disparities stops being an aspiration in strategic plans and becomes a measurable, repeatable quality improvement target.

Subject of Research: Health equity informed implementation science blueprint for reducing breast cancer screening disparities

Article Title: Design of an implementation blueprint to reduce breast cancer disparities using health equity informed implementation science frameworks

Article References: Narayan, A. K., Jordan, L. A., Alagoz, E., Shelton, R. C., Brathwaite, C., Neuman, H., Chatfield, M., Zacharias-Andrews, K., Burnside, E. S., Olds, D. M., & Farr, S. L. (2026). Design of an implementation blueprint to reduce breast cancer disparities using health equity informed implementation science frameworks. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15831-1

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15831-1

Keywords: breast cancer, health equity, implementation science, mammography, screening disparities, quality improvement, CFIR, radiology, cancer centers, health services research, sustainability, BMC Health Services Research

The study, published in JAMA Network Open by researchers at Penn State College of Medicine, examined the de-identified health records of 12.6 million American women between the ages of 40 and 64 who received routine mammograms between 2008 and 2019. The team, led by first author Dong-Won Kang of Ajou University in Korea and senior author Chan Shen, Howard E. Morgan Professor in Surgery and professor of public health sciences at Penn State College of Medicine, set out to disentangle the effects of two legislative approaches that prior research had often bundled together. The first approach, notification laws, requires mammography facilities to tell women when a radiologist identifies dense breast tissue on their scan. The second, insurance coverage mandates, requires health insurers to pay for supplemental follow-up tests such as breast ultrasound and magnetic resonance imaging.

The central finding is striking in its asymmetry. Both forms of legislation independently produced modest increases in supplemental imaging, but insurance coverage mandates had nearly four times the impact of notification laws alone. When states required insurers to cover the cost of supplemental ultrasound, use of the procedure rose by roughly 47 additional examinations per 1,000 women screened. Notification laws, by comparison, were associated with about 13 additional ultrasounds per 1,000 women. In other words, telling a woman she has dense breasts opens a door, but paying for what lies beyond that door is what gets most patients through it.

Understanding why this distinction matters requires a brief look at the biology of breast density. Breasts are composed of three tissue types: fibrous connective tissue, glandular tissue and fatty tissue. Women with dense breasts carry proportionally more fibrous and glandular tissue, which appears white on a mammogram. Tumors and other abnormal changes also appear white, which means dense tissue can effectively camouflage malignancies against a bright background, a phenomenon radiologists describe as masking. Compounding the problem, dense tissue cannot be felt during a physical examination and can only be identified through medical imaging, which is precisely why so many women remain unaware of their own density status without legislative intervention.

The legislative landscape that has emerged is far from uniform, and that variation became a key analytical lever for the Penn State team. As Shen explained, some states require notifications to be sent only to women with dense breasts, while others send a general notice to everyone undergoing mammography. Some states include information about supplemental screening options in their notification letters, and others do not. A smaller number of states have gone further with insurance mandates, some covering ultrasound only, some covering MRI only, and some covering both. Pennsylvania offers a concrete example of the progression: the state passed its Breast Density Notification Act in 2013, requiring facilities to inform patients of density findings, and beginning in 2022 it required all health insurers to cover breast ultrasounds and MRIs for women with high-risk conditions, including dense breast tissue. At the federal level, the Food and Drug Administration began requiring mammography facilities to inform all patients about their breast density in 2024, but no federal law mandates coverage for supplemental testing.

Working within the MarketScan national insurance claims database, the researchers analyzed records from women who had continuous insurance coverage for at least six months after their screening mammogram. The population distribution across legislative environments revealed how uneven adoption has been: 21 percent of women in the sample lived in states with dense breast notification laws, and nearly 60 percent of those lived in states whose notifications included information about supplemental screening. Only 7 percent lived in states requiring insurance coverage for ultrasounds, and just 3 percent lived in states requiring MRI coverage. This patchwork allowed the investigators to compare outcomes across policy regimes while controlling for the confounding that had limited earlier studies.

The granularity of the findings extended beyond the headline contrast. Within states that had notification laws, ultrasound uptake was higher when the laws required notices to mention supplemental screening explicitly, and when notices were targeted specifically to women with dense breasts rather than sent to all screening patients. Notification laws were also associated with a small increase in MRI use, on the order of one additional examination per 1,000 women screened. Insurance mandates for MRI, however, produced no statistically significant change in MRI utilization, a result Shen attributed to the fact that patients with a personal or family history of breast cancer were already much more likely to receive MRI imaging, making this modality less responsive to legislative nudges. She also pointed to cost and logistics that the study did not measure directly: MRIs are generally more expensive tests, and there are fewer facilities offering them, which may create accessibility barriers that dampen demand regardless of what insurers are required to pay.

Perhaps the most sobering statistic in the study concerns the overall baseline. Across the entire sample, only 9 percent of women received supplemental ultrasound imaging and a mere 0.6 percent received supplemental MRI within six months of a screening mammogram, despite the fact that more than 40 percent of middle-age and older women have dense breasts. Even in the most supportive policy environments, supplemental imaging remains the exception rather than the rule. The analysis also identified demographic gradients in follow-up care: older women, women living in rural communities, and those with other health conditions were all less likely to obtain supplemental screening, suggesting that geography, comorbidity and age compound the financial barriers that insurance mandates are designed to remove.

Shen was careful to frame the results without overstatement. Not everyone with dense breasts needs supplemental screening, she noted, but a woman first needs to know whether she has dense breasts before she can make that decision in consultation with her healthcare provider. The findings, she argued, point to logistical and geographical barriers that influence whether women pursue follow-up screening, including cost, the availability of imaging facilities and patient preference. While more research is needed, the study offers a roadmap for policymakers seeking to maximize the public health impact of dense breast legislation: notification requirements raise awareness, but coverage requirements convert awareness into action, and the two work best in combination with attention to the practical obstacles that keep rural and older patients away from imaging centers.

For a field in which supplemental screening policy is still being written state by state, the study provides the first large nationwide evidence that the design details of legislation matter enormously. A notification letter that mentions supplemental screening reaches more women than a generic notice, and an insurance mandate reaches roughly four times as many as any letter alone. With the FDA’s federal notification requirement now in effect but coverage decisions left to states and insurers, the Penn State analysis suggests that the next frontier in dense breast policy is not information but access, ensuring that the women who learn about their density can actually afford and reach the tests that might catch what a mammogram missed.

Subject of Research: The effect of dense breast notification laws and insurance coverage mandates on supplemental breast imaging use after mammography

Article Title: Breast density laws linked to higher ultrasound use after mammography

Article References: Breast density laws linked to higher ultrasound use after mammography. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast density, mammography, supplemental screening, breast ultrasound, breast MRI, insurance mandates, notification laws, breast cancer screening, health policy, JAMA Network Open, Penn State College of Medicine, screening disparities

The urgency underlying the agenda was captured early by Chyke Doubeni, MD, MPH, Chief Health Equity Officer at The Ohio State University Wexner Medical Center. Established prevention and screening strategies, he told attendees, have the power to eliminate nearly half of all cancer deaths, yet barriers continue to prevent many Americans from accessing these opportunities. Doubeni warned that new screening technologies carry transformative potential for cancer detection, but that their value will not be realized equitably unless the fragmented delivery processes that risk deepening existing disparities are addressed. His framing set the tone for two days of discussion in which scientific optimism was repeatedly tempered by structural realism: the tools exist, the evidence exists, and the remaining challenge is one of delivery, coverage, and trust.

That tension between knowledge and access was echoed by Darcie Green, Executive Director of Latinas Contra Cancer, who argued that the field knows more than it ever has about preventing cancer, lowering risk, and finding disease earlier, but that too much distance remains between what is known and what people can actually access and benefit from. Green called for closing that distance by bringing excellent care and patient navigation within reach and by engaging patients and communities in shaping the systems meant to serve them. Jody Hoyos, MHA, Chief Executive Officer of the Prevent Cancer Foundation, described how rapidly the paradigm is shifting: cancer prevention is no longer only about avoiding risk, she said, but about using better science, smarter screening, and earlier detection to find cancer before it becomes life-threatening. She added a practical caveat that resonated through the meeting—patients are demanding less invasive and more accessible options, and uptake will only improve if the field responds to that demand.

Day one of the summit focused on broad, population-level strategies, spanning public health infrastructure, tobacco cessation, vaccines against cancer-causing infections, emerging blood-based tests, and artificial intelligence-driven efficiencies in screening programs. Speakers emphasized that these interventions, deployed at scale, represent the clearest near-term opportunity to bend the cancer mortality curve. Mishellene McKinney, MHA, RN, OCN, Vice President of Clinical Programs at Kaiser Foundation Health Plan and Hospitals, offered an integrated delivery perspective, explaining that value-based care models can proactively engage people in prevention and screening through personalized outreach and evidence-based approaches. As both health plan and care provider, Kaiser Permanente, she said, recognizes preventing cancer as a critical part of overall care and is committed to making screening more accessible, equitable, and effective for members and surrounding communities.

The second day shifted to system-level solutions for meeting individual screening needs, particularly among higher-risk populations. Discussions covered hereditary risk assessment, follow-up diagnostics after abnormal findings, out-of-pocket costs, and continuity of care across the full cancer journey. Lisa Schlager, Vice President of Public Policy for FORCE: Facing Our Risk of Cancer Empowered, stressed that cancer risk is not one-size-fits-all: age, family history, genetics, and environmental and lifestyle factors all shape an individual’s probability of disease. Screening and prevention strategies, she argued, should be tailored so patients receive the most appropriate care for their risk profile, and public policies must evolve so patients can access the right interventions at the right time—an approach she said would improve outcomes, save lives, and reduce healthcare costs simultaneously.

Continuity of care emerged as one of the summit’s most persistent themes. Brandon Leonard, MA, Vice President of Government Affairs at LUNGevity Foundation, identified the central systems challenge as ensuring that patients move seamlessly from initial screening through follow-up diagnostics, treatment, and survivorship care. From a policy standpoint, he called for eliminating access barriers by guaranteeing that screening and diagnostics are covered for all eligible patients without burdensome cost-sharing or utilization management requirements. Molly Guthrie of Susan G. Komen reinforced the point with a concrete legislative record: Komen’s Center for Public Policy has led the introduction of, and helped pass, dozens of state bills to remove barriers standing in the way of affordable, accessible breast imaging. Gaps remain, she cautioned, and laws must continue to evolve so that all patients can obtain the screening they need without financial burden—a goal requiring collective action at both state and federal levels.

Disparities in screening access and experience received pointed attention, including for communities often overlooked in mainstream cancer control conversations. Scout, PhD, Executive Director of The LGBTQIA+ Cancer Network, identified medical mistrust as one of the biggest screening barriers for LGBTQIA+ people, citing recent data showing that this barrier has grown notably worse for 75 percent of that population within the last 18 months. Simple, low-cost interventions—welcoming signage, inclusive badges, visible signals of affirmation—can counteract that mistrust, Scout argued, while medical offices that fail to take such steps actively perpetuate disparities. The observation underscored a recurring summit message: equity in cancer screening is built or lost in thousands of small, everyday clinical interactions, not only in federal legislation.

Genetic risk and the promise of precision prevention figured prominently as well. Tuya Pal, MD, a clinical geneticist at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, and Vice-Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, emphasized that access after testing is what actually saves lives. People with inherited genes that elevate cancer risk have tremendous potential to benefit from screening, she noted, but it is not testing alone that improves outcomes—rather, it is accessing appropriate care based on the results. To reap the benefits of genetic testing, the field must ensure that all individuals can obtain recommended screening and preventive measures once a result is in hand. Her comments reframed the national conversation about expanding genetic testing, warning that testing capacity without downstream care is a hollow victory.

Speakers also grappled with how to translate accelerating scientific progress into practical, responsible care. Ernest Hawk, MD, MPH, Head of Cancer Prevention and Population Science at The University of Texas MD Anderson Cancer Center, acknowledged that the science of cancer prevention and screening has advanced remarkably, and that translating that evidence into clinical tools for risk assessment, evidence-based screening programs, and practice standards has already helped save countless lives. Looking ahead to innovations such as multicancer detection tests moving closer to clinical practice, he urged balance: enthusiasm for their potential must be weighed against careful consideration of potential harms, costs, and implications for population health, until rigorous evidence demonstrates meaningful improvements in outcomes. Elisa M. Rodriguez, PhD, MS, of Roswell Park Comprehensive Cancer Center, added a patient-centered dimension from her own experience delivering cancer risk information: people do not simply want a risk score or percentage, she said—they want actionable information on what they can do to help protect themselves from developing cancer.

The summit also featured remarks from NCCN’s Chief Medical Officer, Renuka Iyer, MD, and Chief Scientific Officer, Nancy L. Lewis, MD, MBS, FACP, with panels moderated by Clifford Goodman, PhD, a consultant in health care technology and policy, and a series of presentations showcasing effective screening and prevention strategies in action. Attendees could pick up copies of the free NCCN Guidelines for Patients on screening and prevention—covering breast cancer screening and diagnosis, colorectal screening, genetic testing, lung cancer screening, and prostate cancer screening—all available in English and Spanish at NCCN.org/patients through funding from the NCCN Foundation. The organization’s next convening, the annual Patient Advocacy Summit on December 3, 2026, also in Washington, D.C., will turn to advancing family-centered cancer care, examining gaps in government support, awareness of assistance programs, and caregiver information. For a field that can already prevent roughly half of cancer deaths with tools in hand, the summit’s collective message was clear: the next frontier is not discovery, but delivery.

Subject of Research: Cancer prevention and screening policy, equity, and access discussed at the NCCN Oncology Policy Summit

Article Title: Cancer prevention and screening takes center stage during DCSummit convened by NCCN

Article References: Cancer prevention and screening takes center stage during DCSummit convened by NCCN. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NCCN, cancer prevention, cancer screening, health equity, National Cancer Institute, CDC, genetic testing, early detection, health policy, patient advocacy, multicancer detection tests, screening disparities